Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

NCT05292950 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

78

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor business decision

Conditions

Asthma
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: ARO-MUC5AC
DRUG: Placebo

Sponsor

Arrowhead Pharmaceuticals